ASAyako Sasaki

Ayako Sasaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayako Sasaki has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Kiyoshi Hayasaka

    Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan

    2 shared publications
  • Atsuhiko Sugiyama

    Department of Neurology, Graduate School of Medicine, Chiba University, Japan

    1 shared publication
  • Atsuhiro Matsuno

    Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan

    1 shared publication
  • Atsushi Fujita

    Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    1 shared publication
  • Eriko Koshimizu

    Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    1 shared publication
  • Fumiaki Tanaka

    Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    1 shared publication

Latest Publications

  • Open Access

    Rapid and comprehensive diagnostic method for repeat expansion diseases using nanopore sequencing

    by Satoko Miyatake, Eriko Koshimizu, Atsushi Fujita, Hiroshi Doi, Masaki Okubo, Taishi Wada, Kohei Hamanaka, Naohisa Ueda, Hitaru Kishida, Gaku Minase, et al.

    We developed a diagnostic method for repeat expansion diseases using a long-read sequencer to improve currently available, low throughput diagnostic methods. We employed the real-time target enrichment system of the nanopore GridION sequencer using the adaptive sampling option, in which software-based target assignment is available without prior sample enrichment, and built an analysis pipeline that prioritized the disease-causing loci. Twenty-two patients with various neurological and neuromuscular diseases, including 12 with genetically diagnosed repeat expansion diseases and 10 manifesting cerebellar ataxia, but without genetic diagnosis, were analyzed. We first sequenced the 12 molecularly diagnosed patients and accurately confirmed expanded repeats in all with uniform depth of coverage across the loci. Next, we applied our method and a conventional method to 10 molecularly undiagnosed patients. Our method corrected inaccurate diagnoses of two patients by the conventional method. Our method is superior to conventional diagnostic methods in terms of speed, accuracy, and comprehensiveness.


  • A novel PHOX2B gene mutation in an extremely low birth weight infant with congenital central hypoventilation syndrome and variant Hirschsprung's disease

    by Yuichiro Miura, Tatsuya Watanabe, Toshihiko Uchida, Tatsuro Nawa, Naobumi Endo, Taichi Fukuzawa, Ryuji Ohkubo, Junji Takeyama, Ayako Sasaki, Kiyoshi Hayasaka


  • Novel PHOX2B mutations in congenital central hypoventilation syndrome

    by Ayako Sasaki, Yumiko Kishikawa, Reisuke Imaji, Yu Fukushima, Yukiko Nakamura, Yutaka Nishimura, Megumi Yamada, Yoichi Mino, Tetsuo Mitsui, Kiyoshi Hayasaka

    Background: Congenital central hypoventilation syndrome (CCHS) is caused by mutation of paird‐like homeobox 2B (PHOX2B). Approximately 90% of patients were found to carry polyalanine repeat expansion mutation (PARM), and the remaining 10% had non‐PARM (NPARM). In PARM, the length of the polyalanine expansion correlates with clinical disease severity. Most patients with NPARM have hypoventilation symptoms in the neonatal period and complications of Hirschsprung disease, dysregulation of autonomic nervous system, and tumors of neural crest origin. Data on the genotype–phenotype association may contribute to the clinical management of the disease.Methods: We studied the genetic background of Japanese CCHS patients according to PHOX2B sequencing.Results: Of 133 Japanese CCHS patients we identified 12 patients carrying 11 different NPARM (approx. 9% of the patients) and described the clinical manifestations in seven of them with the following novel mutations: c.941‐945del5, c.678_693dup16, c.609_616del8, c.620_633del14, c.663_711del 49, c.448C>G and c.944G>C. All patients had hypoventilation in the neonatal period and also had Hirschsprung disease, with the exception of two patients carrying c.620_633del14 and c.663_711del49 mutations. The patient carrying the c.609_616del8 mutation also had a benign mediastinal tumor.Conclusion: Most patients carrying NPARM had severe symptoms with frequent complications, as in previous reports, and should be carefully monitored for various complications, including neural crest‐derived tumor.